In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir.

Autor: Ng TI; AbbVie, Inc., North Chicago, Illinois, USA teresa.ng@abbvie.com., Krishnan P; AbbVie, Inc., North Chicago, Illinois, USA., Pilot-Matias T; AbbVie, Inc., North Chicago, Illinois, USA., Kati W; AbbVie, Inc., North Chicago, Illinois, USA., Schnell G; AbbVie, Inc., North Chicago, Illinois, USA., Beyer J; AbbVie, Inc., North Chicago, Illinois, USA., Reisch T; AbbVie, Inc., North Chicago, Illinois, USA., Lu L; AbbVie, Inc., North Chicago, Illinois, USA., Dekhtyar T; AbbVie, Inc., North Chicago, Illinois, USA., Irvin M; AbbVie, Inc., North Chicago, Illinois, USA., Tripathi R; AbbVie, Inc., North Chicago, Illinois, USA., Maring C; AbbVie, Inc., North Chicago, Illinois, USA., Randolph JT; AbbVie, Inc., North Chicago, Illinois, USA., Wagner R; AbbVie, Inc., North Chicago, Illinois, USA., Collins C; AbbVie, Inc., North Chicago, Illinois, USA.
Jazyk: angličtina
Zdroj: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2017 Apr 24; Vol. 61 (5). Date of Electronic Publication: 2017 Apr 24 (Print Publication: 2017).
DOI: 10.1128/AAC.02558-16
Abstrakt: Pibrentasvir (ABT-530) is a novel and pan-genotypic hepatitis C virus (HCV) NS5A inhibitor with 50% effective concentration (EC 50 ) values ranging from 1.4 to 5.0 pM against HCV replicons containing NS5A from genotypes 1 to 6. Pibrentasvir demonstrated similar activity against a panel of chimeric replicons containing HCV NS5A of genotypes 1 to 6 from clinical samples. Resistance selection studies were conducted using HCV replicon cells with NS5A from genotype 1a, 1b, 2a, 2b, 3a, 4a, 5a, or 6a at a concentration of pibrentasvir that was 10- or 100-fold over its EC 50 for the respective replicon. With pibrentasvir at 10-fold over the respective EC 50 , only a small number of colonies (0.00015 to 0.0065% of input cells) with resistance-associated amino acid substitutions were selected in replicons containing genotype 1a, 2a, or 3a NS5A, and no viable colonies were selected in replicons containing NS5A from other genotypes. With pibrentasvir at 100-fold over the respective EC 50 , very few colonies (0.0002% of input cells) were selected by pibrentasvir in genotype 1a replicon cells while no colonies were selected in other replicons. Pibrentasvir is active against common resistance-conferring substitutions in HCV genotypes 1 to 6 that were identified for other NS5A inhibitors, including those at key amino acid positions 28, 30, 31, or 93. The combination of pibrentasvir with HCV inhibitors of other classes produced synergistic inhibition of HCV replication. In summary, pibrentasvir is a next-generation HCV NS5A inhibitor with potent and pan-genotypic activity, and it maintains activity against common amino acid substitutions of HCV genotypes 1 to 6 that are known to confer resistance to currently approved NS5A inhibitors.
(Copyright © 2017 Ng et al.)
Databáze: MEDLINE
Externí odkaz: